Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly C Nelson

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Journal of Cutaneous Pathology|July 31, 2019
Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literatureHaider A Mejbel, Kelly C Nelson, Dinesh Pradhan, et al.
Cancer Causes & Control : CCC|February 29, 2024
Persistent poverty and incidence-based melanoma mortality in TexasKarla Madrigal, Lillian Morris, Kehe Zhang, et al.
Journal of Cutaneous Pathology|April 18, 2018
Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic featuresTsetan Dolkar, Celestine M Trinidad, Kelly C Nelson, et al.
Journal of Cutaneous Pathology|April 11, 2018
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous patternCelestine Trinidad, Kelly C Nelson, Isabella C Glitza Oliva, et al.
Journal for Immunotherapy of Cancer|February 14, 2018
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsMichael T Tetzlaff, Kelly C Nelson, Adi Diab, et al.
Journal of Cutaneous Pathology|June 5, 2026
Dermatologic Toxicities Associated With Novel Pan-RAS/RAF InhibitorsLin J He, Shaymaa Hegazy, Phyu P Aung, et al.
Journal of Cutaneous Pathology|September 7, 2022
The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapyRiyad N H Seervai, Sarah K Friske, Emily Y Chu, et al.
Journal of the American Academy of Dermatology|January 9, 2018
Management strategies of academic pigmented lesion clinic directors in the United StatesKelly C Nelson, Douglas Grossman, Caroline C Kim, et al.
Journal of Cutaneous Pathology|October 8, 2021
Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapyRiyad N H Seervai, Woo Cheal Cho, Emily Y Chu, et al.
Journal of Cutaneous Pathology|May 13, 2020
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinomaMario L Marques-Piubelli, Michael T Tetzlaff, Priyadharsini Nagarajan, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Journal of Cutaneous Pathology|July 31, 2019
Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literatureHaider A Mejbel, Kelly C Nelson, Dinesh Pradhan, et al.
Cancer Causes & Control : CCC|February 29, 2024
Persistent poverty and incidence-based melanoma mortality in TexasKarla Madrigal, Lillian Morris, Kehe Zhang, et al.
Journal of Cutaneous Pathology|April 18, 2018
Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic featuresTsetan Dolkar, Celestine M Trinidad, Kelly C Nelson, et al.
Journal of Cutaneous Pathology|April 11, 2018
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous patternCelestine Trinidad, Kelly C Nelson, Isabella C Glitza Oliva, et al.
Journal for Immunotherapy of Cancer|February 14, 2018
Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patientsMichael T Tetzlaff, Kelly C Nelson, Adi Diab, et al.
Journal of Cutaneous Pathology|June 5, 2026
Dermatologic Toxicities Associated With Novel Pan-RAS/RAF InhibitorsLin J He, Shaymaa Hegazy, Phyu P Aung, et al.
Journal of Cutaneous Pathology|September 7, 2022
The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapyRiyad N H Seervai, Sarah K Friske, Emily Y Chu, et al.
Journal of the American Academy of Dermatology|January 9, 2018
Management strategies of academic pigmented lesion clinic directors in the United StatesKelly C Nelson, Douglas Grossman, Caroline C Kim, et al.
Journal of Cutaneous Pathology|October 8, 2021
Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapyRiyad N H Seervai, Woo Cheal Cho, Emily Y Chu, et al.
Journal of Cutaneous Pathology|May 13, 2020
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinomaMario L Marques-Piubelli, Michael T Tetzlaff, Priyadharsini Nagarajan, et al.
Pageof 9